![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, October 03, 2023 6:41:15 AM
We are exactly 20 days from the end of the SPAC timeframe, also ( remember this SPAC was not actually setup at first or second with Enzolytics as the target ), yes they could take a vote to extend , but who after 2 years no results filings late , NASDAQ delisting letters would let Barry K have more time. Without solid proof is this worth a 450m purchase and still needing a PIPE to continue something would be needed for my vote. Again hard solid test results , starting projects on time., SEC filings and audits from Enzolytics. To have partnership are great are they purely that a working relationship or a partnership that is willing to finance the hard times for the better times in the future. So far we haven't seen any of thoses big names step up in that manner. We will just use round numbers 275m each pretty sure Intel, Samsung could handle that either as partners or go it alone. Here is a section from Samsung this would suggest they want a cure to happen so why no funding? When you reread it, its more of a business transaction between them than a partnership to continue as equal profitable business relations. Enzolytics uses that partners meaning a little different when used in PRs. If they were really the one to carry Enzolytics to the finish line there would be financial backing or a buy in or total buyout, there would have been a better pathway setup in Africa to insure every ( T ) and every dot was handled correctly, every detailed needed laid out and followed to the ( T ) and on time. If the cure is held by Enzolytics would you think Samsung would want to bring it to mankind to show that they have arrived into the Biopharmaceutical world? link from where the below was taking from
https://www.prnewswire.com/news-releases/enzolytics-inc-and-samsung-biologics-announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2-monoclonal-antibody-therapies-301394969.html
"Partnering with Enzolytics reinforces the value of our fully integrated, end-to-end business model, which is designed to meet the unique needs and goals of our biotech clients," said John Rim, CEO of Samsung Biologics. "We look forward to providing comprehensive services and professional support for the manufacturing of this important class of Monoclonal Antibody therapeutics for the treatment of HIV and SARS-CoV-2, helping to accelerate the process of drug development to IND filing and bring these life-saving products to patients."
"The collaboration with Samsung Biologics is a significant milestone for Enzolytics' Artificial Intelligence enabled Monoclonal Antibody Platform. We chose to partner with Samsung Biologics because of Samsung Biologics' extensive experience and expertise in developing, producing, and manufacturing Monoclonal Antibodies for Infectious Diseases and Oncology." said Dr. Gaurav Chandra, Chief Operating Officer Research and Development at Enzolytics. "This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralizing Monoclonal Antibodies and reduce time to the clinic and offer the much-needed treatment for patients."
GLTA and happy trading today.
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM